COMPARISON
Liraglutide vs Semaglutide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Liraglutide is authorised or registered in 10 and Semaglutide in 10 of the 10 registers read. Liraglutide: highest phase Phase 4 (after approval). Semaglutide: highest phase Phase 4 (after approval). 41 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Liraglutide | Semaglutide | |
|---|---|---|
| Registered trials differs | 518 clinicaltrials.gov · 2026-10-03 | 861 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Liraglutide openfda · 2026-10-03T17:23:44.062Z | FDA-approved: OZEMPIC openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2009-06-30 ema · 2026-10-03 | 2018-02-08 ema · 2026-10-03 |
| ATC code differs | A10BJ02 ema · 2026-10-03 | A10BJ06 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Liraglutide | placebo | Semaglutide | placebo |
|---|---|---|---|---|
| Nausea | 26.4% | 7.4% | 19.5% | 4.5% |
| Diarrhoea | 13.1% | 6.1% | 11.8% | 4.5% |
| Nasopharyngitis | 12.4% | 9.3% | 7.5% | 6.1% |
| Vomiting | 9.0% | 2.1% | 8.6% | 1.6% |
| Constipation | 8.8% | 3.1% | 8.9% | 2.8% |
| Headache | 8.3% | 5.9% | 4.0% | 2.1% |
| Decreased appetite | 6.6% | 1.2% | 6.3% | 1.3% |
| Upper respiratory tract infection | 6.0% | 4.7% | 2.7% | 1.9% |
| Dyspepsia | 5.3% | 1.3% | 5.3% | 1.2% |
| Hypoglycaemia | 8.7% | 3.3% | - | - |
| COVID-19 | - | - | 17.0% | 17.8% |
Trial register Liraglutide: 42 placebo-controlled trials; Semaglutide: 50. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Liraglutide side effects · Semaglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Liraglutide | Semaglutide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
41 registered trials include both
| NCT06836284 | The Evira Study: Additional Support During Obesity Treatment RECRUITING · updated 2026-09-10 |
|---|---|
| NCT07787936 | GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry NOT_YET_RECRUITING · updated 2026-08-26 |
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
| NCT06374875 | Fibrosis Lessens After Metabolic Surgery RECRUITING · updated 2026-07-31 |
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists RECRUITING · updated 2026-07-24 |
| NCT07225816 | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide RECRUITING · updated 2026-07-21 |
| NCT07677865 | GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation COMPLETED · updated 2026-07-01 |
| NCT07640139 | Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes ENROLLING_BY_INVITATION · updated 2026-06-10 |
| NCT07107334 | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients Wit RECRUITING · updated 2026-06-08 |
| NCT07539584 | Adiponectin in Patients With Metabolic Disorders COMPLETED · updated 2026-04-22 |
| NCT06903923 | Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy RECRUITING · updated 2026-04-17 |
| NCT07027969 | Metabolic Surgery for Atrial Fibrillation Elimination NOT_YET_RECRUITING · updated 2026-04-17 |
| NCT05390892 | PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes RECRUITING · updated 2026-04-13 |
| NCT05925959 | Preoperative Weight Loss for Open Abdominal Wall Reconstruction RECRUITING · updated 2026-03-23 |
| NCT03498001 | Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging COMPLETED · updated 2026-02-04 |
| NCT05579249 | A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America COMPLETED · updated 2026-01-14 |
| NCT07325435 | Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists ACTIVE_NOT_RECRUITING · updated 2026-01-08 |
| NCT07309094 | Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD RECRUITING · updated 2025-12-30 |
| NCT06533527 | Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy COMPLETED · updated 2025-12-05 |
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Rea ACTIVE_NOT_RECRUITING · updated 2025-09-23 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.